Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway

Yue, Jing; Li, Jiaojiao; Ma, Junlan; Zhai, Yan; Shen, Li; Zhang, Wei; Li, Lijuan; Fu, Rong

doi:10.1080/16078454.2023.2166333

Cited by 8 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, Mezger et al concurrently engineered NK-92 cells with knock-out of both CBLB and TIGIT, resulting in enhanced cytotoxicity of NK cells [ 175 ]. Also, inhibiting TIGIT/CD155 restored NK cell function in myelodysplastic syndromes (MDS) [ 176 ]. As is the case with B cells, TIGIT could curtail B-cell activation and proliferation as a crucial part of an immune shutdown mechanism, which is critical in minimizing immune-induced tissue damage [ 177 ].…”

Section: Tigit In Preclinical Studiesmentioning

confidence: 99%

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Zhang,

Liu,

et al. 2024

Biomark Res

View full text Add to dashboard Cite

As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion. As the primary ligand of TIGIT in humans, CD155 may be the main target for immunotherapy due to its interaction with TIGIT. It has been found that the anti-programmed cell death protein 1 (PD-1) treatment response in cancer immunotherapy is correlated with CD155 but not TIGIT. Anti-TIGIT alone and in combination with anti-PD-1 agents have been tested for cancer immunotherapy. Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.

show abstract

Section: Tigit In Preclinical Studiesmentioning

confidence: 99%

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Zhang,

Liu,

et al. 2024

Biomark Res

View full text Add to dashboard Cite

show abstract

“…The inhibitory effect of MDSCs on NKG2D expression and IFN-γ production in NK cells was confirmed in both in vivo and in vitro experiments [ 103 ]. The downregulation of other types of NK cell activating receptors, such as NKp30 and NKp46, was also detected [ 104 , 105 ]. Further analysis in a murine lymphoma model revealed that MDSCs, which can secrete IL-10, reduced the frequency of NK cells [ 101 ].…”

Section: Nk Cell Defects In Nhlmentioning

confidence: 99%

“…Further analysis in a murine lymphoma model revealed that MDSCs, which can secrete IL-10, reduced the frequency of NK cells [ 101 ]. Additionally, the coculture of MDSCs with NK cells has been shown to negatively affect the degranulation capacity of these cells through the TIGIT/CD155 pathway [ 105 ].…”

Section: Nk Cell Defects In Nhlmentioning

confidence: 99%

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective

Bakhtiyaridovvombaygi,

Yazdanparast,

Kheyrandish

et al. 2024

Biomark Res

View full text Add to dashboard Cite

Non-Hodgkin lymphomas (NHLs) are heterogeneous and are among the most common hematological malignancies worldwide. Despite the advances in the treatment of patients with NHLs, relapse or resistance to treatment is anticipated in several patients. Therefore, novel therapeutic approaches are needed. Recently, natural killer (NK) cell-based immunotherapy alone or in combination with monoclonal antibodies, chimeric antigen receptors, or bispecific killer engagers have been applied in many investigations for NHL treatment. The functional defects of NK cells and the ability of cancerous cells to escape NK cell-mediated cytotoxicity within the tumor microenvironment of NHLs, as well as the beneficial results from previous studies in the context of NK cell-based immunotherapy in NHLs, direct our attention to this therapeutic strategy. This review aims to summarize clinical studies focusing on the applications of NK cells in the immunotherapy of patients with NHL.

show abstract